Advent agrees to buy majority stake in NZ Clinical Research Group

• Advent agreed to buy a majority stake in New Zealand Clinical Research Group, a clinical trials and medical research operator in New Zealand and Australia.
• Clinician shareholders, management, and Waterman Capital will keep a significant minority stake; financial terms were not disclosed.
• The deal targets expansion across the clinical trial spectrum, with emphasis on deeper sponsor and CRO relationships.
• Closing is expected in Q4 2026, subject to customary regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Advent International Corporation published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.